SSG
FLNA

Summit Securities Group’s Filana Therapeutics FLNA Stock Holding History

Summit Securities Group’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,647
Closed -$2.98K – 1308
2025
Q2 		$2.98K Buy
1,647
+1,543
+1,484% +$2.75K ﹤0.01% 1010
2025
Q1 		$156 Buy
+104
New +$262 ﹤0.01% 740
2024
Q2 		– Sell
-109
Closed -$2K – 761
2024
Q1 		$2K Buy
+109
New +$2.51K ﹤0.01% 389
2013
Q3 		– Sell
-43
Closed -$1K – 536
2013
Q2 		$1K Buy
+43
New +$909 ﹤0.01% 544

Other funds holding FLNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Summit Securities Group's FLNA Position: Q3 2025 in Review

Summit Securities Group sold out of Filana Therapeutics (FLNA) in Q3 2025, closing a stake of 1,647 shares — an estimated $2.98K sold.

Summit Securities Group first reported a position in FLNA in Q2 2013 and held it in 4 quarters. The position peaked at $2.98K in Q2 2025. 103 funds tracked by Wall St. Rank hold FLNA as of Q3 2025.

  • Summit Securities Group reported no remaining Filana Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Summit Securities Group sold 1,647 Filana Therapeutics shares in Q3 2025, an estimated $2.98K.
  • Summit Securities Group first reported a position in Filana Therapeutics in Q2 2013 and held it in 4 quarters.
  • Summit Securities Group's Filana Therapeutics position peaked at $2.98K in Q2 2025.
  • 103 funds tracked by Wall St. Rank held Filana Therapeutics as of Q3 2025.

Based on Summit Securities Group's 13F filing for Q3 2025, filed 13 Nov 2025.